|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
2,238,000 |
Market
Cap: |
872.82(K) |
Last
Volume: |
426,351 |
Avg
Vol: |
423,092 |
52
Week Range: |
$0.236 - $2.75 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Cyclacel Pharmaceuticals is a clinical-stage biopharmaceutical company working to develop cancer medicines based on cell cycle, transcriptional regulation and mitosis control biology. The transcriptional regulation program is evaluating fadraciclib, a Cyclin Dependent Kinase 2/9 (CDK2/9) inhibitor, in solid tumors and hematological malignancies. The anti-mitotic program is evaluating CYC140, a Polo-Like-Kinase 1(PLK 1) inhibitor, in cancers. CDKs are a family of enzymes discovered as regulators of the cell cycle. PLK1 is a serine/threonine kinase with a central role in cell division, or the mitotic phase of the cell cycle, and is a regulator of the DNA damage checkpoint.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
7,956 |
Total Buy Value |
$0 |
$0 |
$0 |
$26,374 |
Total People Bought |
0 |
0 |
0 |
2 |
Total Buy Transactions |
0 |
0 |
0 |
2 |
Total Shares Sold |
215,055 |
215,055 |
194,843,875 |
194,843,875 |
Total Sell Value |
$1,235,395 |
$1,235,395 |
$6,743,391 |
$6,743,391 |
Total People Sold |
3 |
3 |
3 |
3 |
Total Sell Transactions |
5 |
5 |
6 |
6 |
End Date |
2025-07-17 |
2025-04-15 |
2024-10-15 |
2023-10-16 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Fitters Diversified Berhad |
10% Owner |
|
2025-10-10 |
4 |
S |
$5.26 |
$270,261 |
D/D |
(51,400) |
505,758 |
|
- |
|
Fitters Diversified Berhad |
10% Owner |
|
2025-10-08 |
4 |
S |
$5.29 |
$751,606 |
D/D |
(142,000) |
557,158 |
|
- |
|
Kua Khai Loon |
10% Owner |
|
2025-09-16 |
4 |
S |
$5.13 |
$128,300 |
D/D |
(25,000) |
338,160 |
|
- |
|
Kua Khai Loon |
10% Owner |
|
2025-09-12 |
4 |
S |
$6.22 |
$138,490 |
D/D |
(22,251) |
363,160 |
|
- |
|
Fitters Diversified Berhad |
10% Owner |
|
2025-09-12 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
699,158 |
|
- |
|
Kua Khai Loon |
10% Owner |
|
2025-09-05 |
4 |
S |
$7.01 |
$133,569 |
D/D |
(19,054) |
385,411 |
|
- |
|
Kua Khai Loon |
10% Owner |
|
2025-09-04 |
4 |
A |
$0.00 |
$0 |
D/D |
186,465 |
404,465 |
|
- |
|
Ong Yee Lung |
10% Owner |
|
2025-09-04 |
4 |
A |
$0.00 |
$0 |
D/D |
186,465 |
404,465 |
|
- |
|
Yap Kim Choy |
10% Owner |
|
2025-09-04 |
4 |
A |
$0.00 |
$0 |
D/D |
186,465 |
404,465 |
|
- |
|
Yap Kim Choy |
10% Owner |
|
2025-09-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
218,000 |
|
- |
|
Ong Yee Lung |
10% Owner |
|
2025-09-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
218,000 |
|
- |
|
Kua Khai Loon |
10% Owner |
|
2025-09-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
218,000 |
|
- |
|
Lazar David E. |
10% Owner |
|
2025-07-30 |
4 |
S |
$12.36 |
$83,430 |
D/D |
(6,750) |
155,838 |
|
- |
|
Tan Kok Hui |
10% Owner |
|
2025-04-29 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
250,000 |
|
- |
|
Ho Kee Wee |
10% Owner |
|
2025-04-29 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
250,000 |
|
- |
|
Suria Sukses Engineering Sdn Bhd |
10% Owner |
|
2025-04-29 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
250,000 |
|
- |
|
Doris Wong Sing Ee |
Chief Executive OfficerOfficer |
|
2025-02-26 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
194,628,820 |
|
- |
|
Lazar David E. |
Interim CEO |
|
2025-02-26 |
4 |
S |
$0.03 |
$5,507,996 |
D/D |
(194,628,820) |
0 |
|
- |
|
Lazar David E. |
Interim CEO |
|
2025-02-26 |
4 |
OE |
$0.00 |
$0 |
D/D |
194,628,820 |
194,628,820 |
|
- |
|
Natan David |
Director |
|
2025-01-02 |
4 |
A |
$0.00 |
$0 |
D/D |
100,000 |
100,000 |
|
- |
|
Schwartz Brian |
Interim Chief Medical Officer |
|
2024-01-29 |
4 |
A |
$0.00 |
$0 |
D/D |
12,500 |
15,205 |
|
- |
|
Mcbarron Paul |
See Remarks |
|
2023-12-21 |
4 |
B |
$3.32 |
$6,252 |
D/D |
1,886 |
33,378 |
2.81 |
- |
|
Rombotis Spiro |
President and CEO |
|
2023-12-21 |
4 |
B |
$3.32 |
$20,122 |
D/D |
6,070 |
68,658 |
2.81 |
- |
|
Barker Sam L |
Director |
|
2023-06-30 |
4 |
A |
$0.00 |
$0 |
D/D |
21,219 |
40,415 |
|
- |
|
Spiegel Robert J. |
Director |
|
2023-06-30 |
4 |
A |
$0.00 |
$0 |
D/D |
21,219 |
39,415 |
|
- |
|
51 Records found
|
|
Page 1 of 3 |
|
|